由於學名藥TatumcefÒ（ceftazidime 500mg/vial）已通過衛生署Bioavailability/Bioequivalence（BA/BE）試驗引進臺大醫院，為確定其產品品質，進行本試驗，比較不同廠牌的ceftazidime﹙即中化公司的TatumcefÒ 500mg/vial與禮來公司的KefadimÒ 500mg/vial﹚的藥品不良反應發生率，以確定TatumcefÒ的安全性，並確認兩者在療效上並無統計學上顯著的差異。
本研究為一前瞻性、隨機分配、單盲的對照研究，經過台大醫院倫理委員會同意不需簽署病患知情同意書。病房醫師依隨機變數開給不同廠牌的ceftazidime（TatumcefÒ 500mg/vial或KefadimÒ 500mg/vial），而病人未予告知使用何種廠牌藥品，如此以維持單盲條件。
主要研究終點是此兩種廠牌ceftazidime藥品不良反應發生率。次要終點是臨床反應、細菌學反應、藥品花費、劑量、療程及藥品不良反應事件發生時的處置。
本研究於民國九十年三月一日起，在台大醫院心臟外科加護病房、一般外科加護病房以及腦神經外科加護病房進行。原本預計每組至少須收納位268病人，兩組共計536人。但於實驗中期，禮來公司為確保產品品質回收Kefadim®，實驗因而被迫終止，一共收入 148 位病人。排除試驗期中給錯廠牌者後，Kefadim® 組有 68 位病人，Tatumcef® 組有 59 位病人，共127 位的資料可以作分析。
此兩組病人在基本資料、ceftazidime劑量使用的合理性以及併用的抗生素都沒有統計上的差異。研究期間Kefadim®組有13位病人發生14件藥品不良反應，Tatumcef®組有8位病人發生8件不良反應事件。藥品不良反應發生率（發生人數/總人數）分別為19.1 % 及13.6 %，兩組無統計上的差異。分就所發生的不良反應做分析，亦無統計上的差異。
所有觀察到的不良反應包括癲癇，腹瀉、紅疹、搔癢、蕁麻疹、注射部位疼痛、嗜伊性紅血球增多症、血小板減少症、alanine amino transferase（ALT）升高、alkaline phosphatase（ALP）升高、gamma-glutamyl trasnferase（g-GT）升高。其中發生率最高為皮膚紅疹（5-6 %）、血小板減少症（2-4 %）及注射部位疼痛（1-4 %），其他發生率約為1-2 %。
兩種廠牌在藥品不良反應嚴重度及藥品不良反應與ceftazidime相關性的比較方面亦無統計上的差異。
兩種廠牌在臨床反應、細菌學反應、藥品花費、劑量、療程及藥品不良反應事件發生時的處置無統計上的差異。

目錄
內容目錄……………………………………………………………….I
表目錄………………………………………………..…….………….III
圖目錄…………..………………………………………….…………..V
中英文名詞對照………………………………………………………1
中文摘要…………..………………………………………………..…..5
英文摘要…………..……………………………………………………7
第一章 前言……...……………………………………………………..9
第二章 文獻探討………………..……………………………………10
第一節 Ceftazidime 簡介…………………………………………10
一、 Ceftazidime 的藥品動態學………………………….11
二、 Ceftazidime 的劑量………………………………….14
第二節 Ceftazidime 的藥品不良反應……………………………18
一、 Ceftazidime 藥品不良反應的簡介………………….18
二、 Ceftazidime 的藥品不良反應發生率……………….18
第三節 藥品不良反應……………………………………………..23
一、 藥品不良反應定義…………………………………...23
二、 藥品不良反應與可疑藥品的相關性評估…………...23
第三章 研究目的………………..…………………………………....29
第四章 研究設計與方法……………………………………………30
第一節 研究終點………………………………………………….31
第二節 研究藥品及研究對象…………………………………….32
第三節 研究方法………………………………………………….36
一、 本研究中的各項評估項目及定義…………………..37
二、 資料收集……………………………………………...44
三、 研究樣本數的預估及數據分析……………………...45
第五章 結果………………………………………,,,…………………47
第一節 基本資料…………………………………………………..47
第二節 Ceftazidime 使用劑量的合理性評估……………………53
第三節 併用的抗生素……………………………………………..57
第四節 不同廠牌的Ceftazidime藥品不良反應…………………59
第五節 不同廠牌的Ceftazidime藥品不良反應處理方式………66
第六節 藥品不良反應與Ceftazidime的使用劑量……………….71
第七節 不同廠牌的Ceftazidime臨床反應……………………….74
第八節 不同廠牌的Ceftazidime細菌學反應…………………….76
第九節 不同廠牌的Ceftazidime的藥品花費…………………….79
第六章 討論…………………...………………………………………80
第一節 針劑是否需做生物相等性試驗…………………………..80
第二節 採用FDA藥品不良反應定義及Naranjo不良反應相關性評估法的原因……………………………………………..82
第三節 Ceftazidime使用劑量的合理性評估……………………..83
第四節 不同廠牌的Ceftazidime藥品不良反應………………….86
第五節 Ceftazidime引起血小板減少症之探討…………………..90
第六節 不同廠牌的Ceftazidime細菌學反應…………………….92
第七節 探討本試驗臨床反應多為失敗的原因…………………..95
第八節 研究限制…………………………………………………..96
第七章 結論與建議………………………………………..…………98
參考文獻………………………………………………………..……100

1. Webb ML. Research. In: Gennaro AR, Marderosian AHD, Hanson GR, editors. Remington: The Science and Pratice of Pharmacy. 20th ed. Baltimore: Lippincott Williams & Wilkins; 2000.p.81-8.
2. Norrby SR. Ceftazidime in clinical practice — a summary. J Antimicrob Chemother 1983;12(suppl A):405-8.
3. Neu HC. Advances in cephalosporin therapy. Am J Med 1985;79(suppl 2A):114-8.
4. McEvoy GK, Miller JL, Litvak K, editors. American Hospital Formulary Service: Drug Information. Bethesda: American Society of Health-System Pharmacists, Inc.; 2002.p.188-98.
5. 2002年凱復定注射劑中文仿單。
6. Harding SM, Monro AJ, Thronton JE, Ayrton J, Hogg MIJ. The comparative pharmacokinetics of ceftazidime and cefotaxime in healthy vonlunteers. J Antimicrob Chemother 1981;8:263-72.
7. Harding SM, Harper PB. The pharmacokinetic behavior of ceftazidime in man and the relationship between serum levels and the in vitro susceptibility of clinical isolates. Infect 1983;11:S49-53.
8. Luthy R, Blaser J, Bonetii A, Simmen H, Wise R, Siegenthaler W. Comparative multiple-dose pharmacokinetics of ceftaxime, moxalactam, and ceftazidime. Antimicrob Agents Chemother 1981;20:567-75.
9. Yuk-Choi JH, Nightingale CH, Willian TW. Considerations in dosage selection for third generation cephalosporins. Clin Pharmacokinet 1992;22:132-43.
10. McCracken GH, Threlkeld N, Thomas ML. Pharmacokinetics of ceftazidime in newborn infants. Antimicrob Agents Chemother 1984;26:583-4.
11. Mulhall A, De Louvois J. The pharmacokinetics and safety of ceftazidime in the neonate. J Antimicrob Chemother 1985;15:97-103.
12. Prinsloo JG, Delport SD, Moncrieff J, Paton AM. A preliminary pharmacokinetic study of ceftazidime in premature, newborn and small infants. J Antimicrob Chemother 1983;12:361-4.
13. Amato M, Schaad UB. Preliminary experience with ceftazidime monotheraoy in perinatal infection. Helv Paediatr Acta 1987;42:297-303.
14. Tessin I, Thiringer K, Trollfors B, Brorson JE. Comparison of serum concentrations of ceftazidime and tobramycin in newborn infants. Eur J Pediatr 1988;147:405-7.
15. Fass RJ. Comparative in vitro activities of third-generation cephalosporin. Arch Intern Med 1983;143:1743-5.
16. Thornsberry C. Review of in vitro activity of third-generation cephalosporins and other newer beta-lactam antibiotics against clinically important bacteria. Am J Med 1985;79(suppl 2A):14-20.
17. Neu HC, Labthavikul P. Antibacterial activity and β-lactamase stability of ceftazidime, an aminothiazolyl cephalosporin potentially active against Pseudomonas aeruginosa. Antimicrob Agents Chemother 1982;21:11-8.
18. Lipman J, Gomersall CD, Gin T, et al. Continuous infusion ceftazidime in intensive care: a randomized controlled trial. J Antimicrob Chemother 1999;43:309-11.
19. Micromedex computerized clinical information system. Eaglewood: Micromedex, Inc. 2000.
20. Tjandramaga TB, Van Hecken A, Mullie A, et al. Comparative pharmacokinetics of ceftazidime and moxalactam. Antimicrob Agents Chemother 1982;22: 237-41.
21. Harding SM, Harper PB. The pharmacokinetic behavior of ceftazidime in man and the relationship between serum levels and the in vitro susceptibility of clinical isolates. Infect 1983;11(suppl 1):49-53.
22. Wise R, Armstrong GC, Brown RM, et al. The pharmacokinetics and tissue penetration of ceftazidime and cefamandole in healthy volunteers. J Antimicrob Chemother 1981;8(suppl B):277-82.
23. Dumler F, Gottschling L, Umstead G, et al. Intermittent intraperitoneal ceftazidime dosing in end-stage renal disease. ASAIO J 1998; 44:M411-4.
24. Aweeka FT. Dosing of drugs in renal failure. In: Koda-Kimble MA, Young LY, editors. Applied Therapeutics: The Clinical Use of Drugs. 7th ed. Baltimore: Lippincott Williams & Wilkins; 1995.p.32.1-32.21.
25. Norrby SR, Burman LA, Linderholm H and Trollfors B. Ceftazidime: pharmacokinetics in patients and effects on the renal function. J Antimicrob Chemother 1982;10:199-206.
26. Trollfors AB, Olaison AL, SuurkÜlaOM, Norrby SR. Ceftazidime and renal function. J Antimicrob Chemother 1984;13:177-81.
27. Mondorf AW, Heynold FT, Scherberich HH, Schoeppe W. Assessment of the nephrotoxic potential of ceftazidime and a ceftazidime/ tobramycin combination in volunteers. Infect 1983;11(suppl 1): s57-s62.
28. Verhagen CA, Mattie H, Van Strijen E. The renal clearance of cefuroxime and ceftazidime and the effect of probenecid on their tubular excretion. Br J Clin Pharmacol 1994;37:193-7.
29. St Peter WL, Redickill KA, Halstenson CE. Clinical pharmacokinetics of antibiotics in patients with impaired renal function. Clin Pharmacokinet 1992;22:169-210.
30. Benet LZ, Williams RL. Design and optimization of dosage regimens: Pharmacokinetic data. In: Goodman GA, Rall TW, Nies AS, Taylor P, eds. The Pharmacological Basis of Therapeutics, 8th ed. Elmsford, NY, Pergamon Press; 1990.p.1650-735
31. Frank U, Kappstein I, Schmidt-Eisenlohr E et al. Penestration of ceftazidime into heart valves and subcutaneous and muscle tissue of patients undergoing open-heart surgery. Antimicrob Agents Chemother 1987;31:813-14.
32. Cotterill S. Antimicrobial prescribing in patients on hemofiltration. J Antimicrob Chemother 1995;36:773-780.
33. Taketomo CK, Hodding JH and Kraus DM. In: Pediatric Dosage Handbook. 8th ed, 2001-2002.p.201-2.
34. Prober CG, Stevenson DK, Bentiz WE. The use of antibiotics in neonates weighting less than 1200 grams. Pediatr infect Dis J 1990;9:111-21.
35. Low DC, Bissenden JG, Wise R. Ceftazidime in neonatal infections. Arch Dis Child 1985;60:360-4.
36. Boccazzi A, Rizzo M, Caccamo ML, Assael BM. Comparison of the concentrations of ceftazidime in the serum of newborn infants after intravenous and intramuscular administration. Antimicrob Agents Chemother 1983;24:955-6.
37. Van den Anker JN, Schoemaker RC, Hop WCJ et al. Ceftazidime pharmacokinetics in preterm infants: Efects of renal function and gestational age. Clin Pharmacol Ther 1995;58:650-9.
38. Comstock TJ. Assessment of renal function. In: DiPiro JT, Talbert RL, Yee GC, Matzk GR, Wells BG and Posey AM. Pharmacotherapy: A Pathophysiologic Approach. 4th ed. Stamford: Appleton & Lange; 1999.p.706-31.
39. Meyers BR. Comparative toxicities of third-generation cephalosporins. Am J Med 1985;79(suppl 2A):96-103.
40. Neu H. Ceftizoxime: A beta-lactamase-stable, broad-spectrum cephalosporins: pharmacokinetics, adverse effects and clinical use. Pharmacol Ther 1984;4:47-66.
41. Adverse reaction. WHO technical report series No 498 (1972).WHO-OMS World Health Prganization. Available from: URL: http://www.who.int/
42. Department of Health and Human Services. New drug and antibiotic regulations; section 314.80 postmarketing reporting of adverse drug experiences. Fed Reg 1985;50(30):7500-1
43. Karch FE, Smith CL, Kerzner B, et al. Adverse drug reactions- a matter of opinion. Clin Pharmacol Ther 1976;19:489-92.
44. Kramer MS, Leventhal JM, Hutchinson MB, et al. An algorithm for the operational assessment of adverse drug reactions. I. Background, description, and instructions for use. JAMA 1979;242:623-32.
45. Naranjo CA, Sellers EM, Sander P et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30: 239-45.
46. Jones JK. Adverse drug reactions in the community health setting: Approaches to recognizing, counseling, and reporting. Fam Comm Health 1982;5:58-67.
47. Seidl LG, Thornton GF, Smith JW, et al. Studies on the epidemiology of adverse drug reactions. Bull John Hokpins Hosp 1966;119:299-314.
48. Hartwig SC, Siegal J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm 1992;49:2229-32.
49. Anderson PO, Knoben JE, Troutman WG. Handbook of Clinical Drug Data. 10th ed. Stamford: Appleton & Lange;2002.p.1057-60.
50. Schwartz GJ, Brion LP and Spitzer A. The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children and adolescents. Pediatr Clin North Am 1980;37: 195-201.
51. Beers MH and Berkow R. The Merk manual of diagnosis and therapy. 16th ed. N.J: Merk & Co.,Inc; 1999.
52. Boh LE. Clinical clerkship manual. Washington: Applied Therapeutics, Inc; 1999.p.5.7-5.16.
53. Sasich LD, Sukkari SR. Drug-induced blood disorders. In: Koda-Kimble MA, Young LY, Kardjan WA and Guglielmo BJ. Applied Therapeutics: The Clinical Use of Drugs. 7th ed. Philadelphia: Lippincott Williams & Wilkins; 2001.p.85.1-85.21.
54. Mueller BA and Macias WL. Acute renal failure. In: DiPiro JT, Talbert RL, Yee GC, Matzk GR, Wells BG and Posey AM. Pharmacotherapy: A Pathophysiologic Approach. 4th ed. Stamford: Appleton & Lange; 1999.p.706-31.
55. Traub SL. Basic skills in interpreting laboratory data. 2nd ed. Bethesda: American society of health-system pharmacists; 1996.p.242.
56. Strolley P, Srom BL. Sample size calculations for clinical pharmacology studies. Clin Pharmacol Ther 1988:489-90.
57. International Classification of Disease 9th Revision, Clinical Modification. 4th ed. Los Angeles: Practice management information corporation (PMIC); 1994.
58. Malinowski HJ. Bioavailability and bioeqivalence testing. In: Gennaro AR, Marderosian AHD, Hanson GR, editors. Remington: The Science and Pratice of Pharmacy. 20th ed. Baltimore: Lippincott Williams & Wilkins; 2000.p.995-1004.
59. The United States Pharmacopeia: The National Formulary. Asian ed. 2000:2056-98.
60. 中華藥典第五版。行政院衛生署編印。中華民國八十九年，第259-61頁。
61. Michel AJ and Knodel LC. Comparison of three algorithms used to evaluate adverse drug reactions. Am J Hosp Pharm 1986;43:1709-14.
62. Bugge JF. Pharmacokinetics and drug dosing adjustments during continuous venovenous hemofiltration or hemodiafiltration in critically ill patients. Acta anadsthesiol scand 2001;45:929-34.
63. Golper TA and Marx MA. Drug dosing adjustment during continuous renal replacement therapies. Kidney Int 1998;53(suppl. 66): s165-8.
64. Joy MS, Matzk GR, Armstrong DK, Marx MA and Zarowitz BJ. A primer on continuous renal replacement therapy for critically ill patients. Ann Pharmacother 1998; 32:362-75.
65. Frye RF and Matzke GR. Drug therapy individualization for patients with renal insufficiency. In: DiPiro JT, Talbert RL, Yee GC, Matzk GR, Wells BG and Posey AM. Pharmacotherapy: A Pathophysiologic Approach. 4th ed. Stamford: Appleton & Lange; 1999.p.872-89.
66. Cockcroft DW and Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
67. Davies JG, Kingswood JC, Sharpstone P and Street MK. Drug removal in continuous hemofiltration and hemodialysis. Br J Hosp Med 1995; 54:524-28.
68. Taylor CA, Rahman EA, Zimmerman SW and Johnson CA. Clinical pharmacokinetics during continuous ambulatory peritoneal dialysis. Clin Pharmacokinetic 1996;31:293-308.
69. Keller E, Reetze P and Schollmeyer P. Drug therapy in patients undergoing continuous ambulatory peritoneal dialysis: clinical pharmacokinetic consideratiom. Clin Pharmacokinetic 1990;18: 104-17.
70. Bailie GR and Eisele G. Continuous ambulatory peritoneal dialysis: A review of its mechanism, advantages, complications, and areas of controversy. Ann Pharmacother 1992;26:1409-20.
71. Danielson DA. Drug-induced blood disorders. JAMA 1984;252:3257-66.
72. Lown J, Barr A. Immune thrombocytopenia induced by cephalosporins specific for thiomethyltetrazole side chain. J Clin Pathol 1987;40:700-1.
73. Hull R L., and Brandon D. Thrombocytopenia possibly caused by structurally related third-generation cephalosporins. Ann Pharmacother 1991;25:135-6.
74. Cawley MJ, Wittbrodt ET, Boyce EG and Skaar DJ. Potential risk factors associated with thrombocytopenia in a surgical intensive care unit. Pharmacotherapy 1999;19:108-13.
75. “COSTART” Coding symbols for thesaurus of adverse reaction terms. 5th ed. Food and Drug Administration; 1995.